BioSpace News Archive

Neurenati Therapeutics, a pediatric rare diseases-focused company, is delighted to announce the appointment of a highly-experienced executive in the pharma industry as an independent board member.

hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, presented preclinical data supporting its lead program in severe hemophilia A at the American Society of Gene and Cell Therapy Annual Meeting in Baltimore, Md.

Aadi Bioscience today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

TiumBio Co., Ltd. announced positive topline results from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with moderate to severe endometriosis-associated pain.

Xylyx Bio today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor organs to transplant condition.

Acumen Pharmaceuticals, Inc. today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced its first quarter 2024 financial results and provided recent operating highlights for the CNM-Au8 clinical program for MS.

AdvanCell today announced the appointment of two senior management team members.

Precision BioSciences, Inc. today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team.

Cue Biopharma, Inc. announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.